← Leaderboards
Maria L Padilla
National Jewish Health
$1,636,630
Attributed
$4,909,889
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2019–21$2M$1.5M$1M$500K$0
'19
'20
'21
Funding mix
By agency
NIH$4,909,889 · 1
By mechanism
UH3$4,909,889 · 1
Top collaborators
- Gregory Paul Downey3 shared
- Naftali Kaminski3 shared
Most similar at National Jewish Health
Same institution · by research overlap
- Carl W White$29,966,481
- Lisa A Maier$11,952,941
- Monica Kraft$36,612,836
- Gregory Paul Downey$7,242,854
- Karina Serban$2,991,972
Others in their field
Other Emerging Leaders on “Adenoviruses”
- Yunda Huang · Fred Hutchinson Cancer Center$6,300,648
- Michael Daniel Keller · Children'S Research Institute$5,364,897
- Matthew C. Altman · Benaroya Research Inst At Virginia Mason$4,720,035
- Ana Milosevic · Rockefeller University$4,341,388
- Benjamin J Burwitz · Oregon Health & Science University$3,842,980
- Heather M Murphy · Temple Univ Of The Commonwealth$3,703,700
Research focus
AdenovirusesAttenuatedAutomobile DrivingBaseBenchmarkingBioinformaticsBiological MarkersBiomarker DevelopmentBiomarker DiscoveryBiomarker PanelBleomycinBloodBronchoalveolar LavageCancer TypeCandidate MarkerCaringChestChronicCicatrixClinicClinical ApplicationClinical CareClinically RelevantAcute
Grant awards (3)
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$1,511,058
UH3 · FY2021 · TR
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$1,726,316
UH3 · FY2020 · TR
Use of the Src Family Kinase Inhibitor Saracatinib in the Treatment of Pulmonary Fibrosis$1,672,515
UH3 · FY2019 · TR